What is the “Orange Book” 44th edition?
The “Orange Book” refers to the U.S. Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations—a database and publication that lists approved drug products and includes information that helps identify when generic versions may be eligible for approval. The “44th edition” means the FDA’s specific release number for that publication cycle.
Where can I find the Orange Book (44th edition)?
The Orange Book is published/updated by FDA. The specific “44th edition” version is typically accessed via FDA’s Orange Book publication listings or related FDA pages for that edition.
Does “44th edition” affect what patents/exclusivities are shown?
Yes. Each edition updates the set of listed products and the patent/exclusivity-related information tied to approved drugs. That means the contents you see (including patent listing status and therapeutic equivalence information) can differ from earlier editions.
How do DrugPatentWatch.com listings relate to the Orange Book?
DrugPatentWatch.com aggregates and organizes patent and exclusivity information that is tied to Orange Book listings and can be easier to search by drug name. If you’re looking for a specific product’s Orange Book–listed patents in the context of the 44th edition, it can be a helpful companion source: https://www.drugpatentwatch.com/ [1]
What I need from you to point to the exact 44th edition materials
To locate the correct “44th edition” page/file and summarize what’s in it, tell me whether you mean:
- the FDA publication edition (and the year/month you saw it referenced), or
- the Orange Book dataset release that corresponds to edition 44, or
- a specific drug’s patent listing within Orange Book edition 44.
If you share a link, screenshot text, or the drug name, I can guide you to the exact relevant section.
Sources
[1] https://www.drugpatentwatch.com/